Comparative Analysis of Standard and Split-Dose Cisplatin in Neoadjuvant Chemotherapy for Bladder Cancer

Cover Page

Cite item

Full Text

Abstract

Cisplatin-based neoadjuvant chemotherapy (NACT) prior to radical cystectomy (RC) reduces mortality from tumor progression by 33% and achieves complete pathological response (pCR) in one-third of patients. However, the comparative efficacy of different cisplatin dosing regimens remains understudied.

References

  1. Patel V.G., Oh W.K., Galsky M.D. Treatment of muscle invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020; 70(5): 404-423.-DOI: https://doi.org/10.3322/ caac.21631.
  2. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19(3): 666-675.-DOI: https://doi.org/10.1200/JCO.2001.19.3.666.
  3. Lee H.W., Kwon W.A., Nguyen L.N.T., et al. Approaches to clinical complete response after neoadjuvant chemotherapy in muscle-invasive bladder cancer: Possibilities and limitations. Cancers. 2023; 15(4): 1323.-DOI: https://doi.org/10.3390/ cancers15041323.
  4. Witjes J.A., Bruins H.M., Carrión A., et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2023 guidelines. Eur Urol. 2024; 85(1): 17-31.-DOI: https:// doi.org/10.1016/j.eururo.2023.08.016.
  5. Карякин О.Б., Попов А.М. Неоадъювантная химиотерапия рака мочевого пузыря: за и против. Онкоурология. 2006; 2(2): 31-34.-URL: https://oncourology.abvpress.ru/oncur/ article/view/1181/1066. [Karjakin O.B., Popov A.M. Neoadjuvant chemotherapy for bladder cancer: pros and cons. Oncourology. 2006; 2(2): 31-34.-URL: https://oncourology. abvpress.ru/oncur/article/view/1181/1066 (In Rus)].
  6. Gakis G. Management of muscle-invasive bladder cancer in the 2020s: Challenges and perspectives. Eur Urol Focus. 2020; 6(4): 632-638.-DOI: https://doi.org/10.1016/j. euf.2020.01.007.
  7. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349(9): 859-866.-DOI: https://doi.org/10.1056/ NEJMoa022148.
  8. Sherif A., Holmberg L., Rintala E., et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: A combined analysis of two nordic studies. Eur Urol. 2004; 45(3): 297-303.-DOI: https://doi. org/10.1016/j.eururo.2003.09.019.
  9. Трякин А.А., Бесова Н.С., Волков Н.М., et al. Практи ческие рекомендации по общим принципам проведения противоопухолевой лекарственной терапии. Злокачествен ные опухоли. 2021; 10(3S2-1): 26-39.-DOI: https://doi. org/10.18027/2224-5057-2020-10-3s2-01. [Tryakin A.A., Besova N.S., Volkov N.M., et al. Practical recommendations on the general principles of antitumor drug therapy. Malignant Tumors. 2021; 10(3S2-1): 26-39.-DOI: https:// doi.org/10.18027/2224-5057-2020-10-3s2-01 (In Rus)].
  10. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18(17): 3068-3077.-DOI: https:// doi.org/10.1200/JCO.2000.18.17.3068.
  11. Dash A., Pettus J.A., Herr H.W., et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008; 113(9): 2471-2477.-DOI: https://doi.org/10.1002/ cncr.23848.
  12. Sternberg C.N., de Mulder P.H., Schornagel J.H., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001; 19(10): 2638-2646.- DOI: https://doi.org/10.1200/JCO.2001.19.10.2638.
  13. Osterman C.K., Babu D.S., Geynisman D.M., et al. Efficacy of split schedule versus conventional schedule neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer. Oncologist. 2019; 24(5): 688-690.-DOI: https:// doi.org/10.1634/theoncologist.2018-0561.
  14. Brierley J., Gospodarowicz M.K., Wittekind C.H. TNM classification of malignant tumours. 8th ed. New York: John Wiley & Sons, Inc.; 2017; 272. Union for International Cancer Control.-URL: https://www.uicc.org/resources/ tnm-classification-malignant-tumours-8th-edition.
  15. РОО «Ассоциация онкоурологов России». Клинические реко мендации по лечению рака мочевого пузыря. Российское об щество урологов. 2024.-URL: https://oncology-association. ru/wp-content/uploads/2023/11/rak-mochevogo puzyrya_23.pdf. [NGO Association of oncourologists of Russia. Clinical guidelines for the treatment of bladder cancer. Russian Society of Urologists. 2024.-URL: https:// oncology-association.ru/wp-content/uploads/2023/11/rak mochevogo-puzyrya_23.pdf (In Rus)].
  16. Hanna N., Trinh Q.D., Seisen T., et al. Effectiveness of neoadjuvant chemotherapy for muscle-invasive bladder 1312 ВОПРОСЫ ОНКОЛОГИИ. 2025;71(6) doi: 10.37469/0507-3758-2025-71-6-OF-2308 cancer in the current real world setting in the USA. Eur Urol Oncol. 2018; 1(1): 83-90.-DOI: https://doi.org/10.1016/j. euo.2018.03.001.
  17. Scher H.I., Yagoda A., Herr H.W., et al. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol. 1988; 139(3): 470-474.- DOI: https://doi.org/10.1016/s0022-5347(17)42495-5.
  18. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol. 2005; 48(2): 202-205.-DOI: https://doi. org/10.1016/j.eururo.2005.04.006.
  19. Meeks J.J., Bellmunt J., Bochner B.H., et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer. Eur Urol. 2012; 62(3): 523-533. -DOI: https://doi.org/10.1016/j.eururo.2012.05.048.
  20. Harik L., Paner G., Al-Ahmadie H., et al. Protocol for the examination of cystectomy specimens from patients with carcinoma of the urinary bladder. College of American Pathologists; 2023.-URL: https://documents.cap.org/ protocols/Bladder_4.2.0.0.REL_CAPCP.pdf.
  21. Ковылина М.В., Прилепская Е.А., Пушкарь Д.Ю. Пато морфологическая диагностика рака предстательной же лезы, рака мочевого пузыря и рака почки: методические рекомендации № 55. Москва: АБВ-пресс. 2017; 52 .-URL: https://uroweb.ru/sites/default/files/patom.pdf. [Kovylina M.V., Prilepskaya E.A., Pushkar D.Yu. Pathomorphological diagnosis of prostate cancer, bladder cancer, and kidney cancer: Methodological recommendations No. 55. Moscow: ABV-Press. 2017; 52 .-URL: https://uroweb.ru/sites/ default/files/patom.pdf (In Rus)].
  22. Лушников Е.Ф., Абросимов А.Ю., Двинских Н.Ю. Пато морфоз опухолей человека. Москва: СИМК. 2021; 224. [Lushnikov E.F., Abrosimov A.Yu., Dvinskikh N.Yu. Tumor pathomorphosis in humans. Moscow: SIMK. 2021; 224 (In Rus)].
  23. Wang H.J., Solanki S., Traboulsi S., et al. Neoadjuvant chemotherapy-related histologic changes in radical cystectomy: assessment accuracy and prediction of response. Hum Pathol. 2016; 53: 35-40.-DOI: https://doi.org/10.1016/j. humpath.2016.02.011.
  24. Pfister C., Gravis G., Fléchon A., et al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur Urol. 2021; 79(2): 214-221.-DOI: https:// doi.org/10.1016/j.eururo.2020.08.024.
  25. Карякин О.Б., Воробьев Н.В., Заборский И.Н., et al. Неоадъювантная химиотерапия и радикальная цистэкто мия у больных раком мочевого пузыря. Онкоурология. 2022; 18(3): 92-98.-DOI: https://doi.org/10.17650/1726- 9776-2022-18-3-92-98. [Karyakin O.B., Vorobyov N.V., Zaborsky I.N., et al. Neoadjuvant chemotherapy and radical cystectomy in patients with bladder cancer. Oncourology. 2022; 18(3): 92-98.-DOI: https://doi.org/10.17650/1726- 9776-2022-18-3-92-98 (In Rus)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Problems in Oncology

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).